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bronchial biopsy trials in a new randomized
controlled COPD biopsy trial with roflumilast
Neil C Barnes1*, Marina Saetta2 and Klaus F Rabe3Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease mediated by an
array of inflammatory cells and mediators, but above all, CD8+ T-lymphocytes, macrophages and neutrophils are
important players in disease pathogenesis. Roflumilast, a first-in-class, potent and selective phosphodiesterase 4
(PDE4) inhibitor, reduces the rate of exacerbations in patients with a high risk of future exacerbations and has been
shown to reduce inflammatory cells and mediators in induced sputum, a surrogate of airway inflammation. However,
these anti-inflammatory effects are yet to be confirmed in another robust study directly assessing inflammatory markers
in bronchial sub-mucosa.
Methods/Design: An international, 16-week, randomized, double-blind, placebo-controlled, parallel-group study
investigating the effects of roflumilast 500 μg once-daily versus placebo on inflammatory parameters in bronchial
biopsy tissue specimens, sputum and blood serum. One hundred and fifty patients with COPD and chronic bronchitis
for at least 12 months will be recruited into the study and randomized in a 1:1 ratio to receive either roflumilast or
placebo. The primary endpoint will be the number of CD8+ cells (cell counts per mm2) in bronchial biopsy tissue
specimens (sub-mucosa) and the key secondary endpoint will be the number of CD68+ cells (cell counts per
mm2), assessed by indirect immunohistochemistry.
Discussion: It is hypothesized that treatment with roflumilast reduces the characteristic inflammation found in the
airways of patients with moderate-to-severe COPD, compared with placebo. The design of the present study has built
on the work of previous bronchial biopsy studies available in the literature. It is hoped that it will reveal the cellular
mechanisms underlying the anti-inflammatory effects of roflumilast and identify potentially important biomarkers and
other surrogate endpoints in patients with COPD. The design and rationale for this trial are described herein.
Trial registration: Clinical trial identifier: NCT01509677 (clinicaltrials.gov)
Keywords: Chronic obstructive pulmonary disease, Roflumilast, Inflammation, Exacerbation, Bronchoscopy, Bronchial
biopsy, Protocol, Sputum, HistologyBackground
Chronic obstructive pulmonary disease (COPD) is a
major public health problem and it is projected that its
burden will increase over the coming decades [1]. The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) document defines COPD as a “preventable and
treatable disease, characterized by persistent airflow* Correspondence: neil.c.barnes@gsk.com
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reproduction in any medium, provided the orlimitation that is usually progressive and associated with
an enhanced chronic inflammatory response in the air-
ways and the lung to noxious particles or gases. Exacer-
bations and comorbidities contribute to the overall
severity in individual patients” [2].
COPD is a chronic inflammatory disease. Most not-
ably, CD8+ T-lymphocytes, macrophages (CD68+) and
neutrophils are increased in the airways and sputum of
patients with chronic bronchitis and COPD [3-8]. In-
creased CD8+ T-lymphocyte counts have been charac-
terized in the alveolar walls, [8] pulmonary arteries, [8]Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pithelium [4] of patients with COPD. Moreover, neutro-
phil numbers are elevated in the bronchial glands and
epithelium, [6] while increased macrophage infiltration
has been observed in the subepithelium [4] and bronchial
glands of symptomatic patients [6]. In a cross-sectional
study of patients with a wide range of COPD severity,
Hogg and colleagues have shown that the percentage
of airways containing inflammatory cells (including neu-
trophils, macrophages and CD8+ cells), increases with
increasing GOLD stage of COPD [3]. However, the level
of inflammation underlies not only disease severity, but
also exacerbation severity [9] and recovery time [10]. Papi
et al. have observed that the proportion of sputum neu-
trophilia correlates positively with exacerbation severity,
independently of bacterial or viral infections, and that spu-
tum eosinophilia may be a good predictor of an imminent
viral exacerbation [9]. There is also a significant relation-
ship between the differences in interleukin (IL)-6 and IL-8
levels at baseline and day 7 after an exacerbation, and
symptom recovery time, suggesting an important role of
these inflammatory markers [10].
COPD exacerbations are also associated with in-
creased airway and systemic inflammation [11,12]. For
example, patients experiencing a severe exacerbation
have augmented neutrophilic recruitment and gene ex-
pression of neutrophilic chemoattractant proteins com-
pared to controls [11]. IL-6 and IL-8 levels are elevated
in the sputum of patients experiencing an exacerbation
and even in frequent exacerbators who are stable, [12]
while CD8+ T-lymphocytes have been found to be in-
creased at the onset of COPD exacerbations [13,14]. Most
recently, it has been shown that CD8+ T-lymphocytes
actually move from the circulation to the lung following
experimental RV infection in COPD patients [15].
The use of bronchial biopsies has contributed signi-
ficantly to our knowledge of COPD, helping to reveal the
anti-inflammatory properties of COPD therapies, and the
key role of CD8+ T-lymphocytes in COPD pathology
[4,16-18]. One study demonstrated that a salmeterol/fluti-
casone propionate combination reduces CD8+, CD45+
and CD4+ cell numbers, as well as cells expressing genes
for tumor necrosis factor-α (TNFα) [17]. Bourbeau et al.
have confirmed that the same combination has anti-
inflammatory effects which are not observed with use of
the inhaled corticosteroid alone [16].
Roflumilast is a first-in-class, potent and selective phos-
phodiesterase 4 (PDE4) inhibitor, which targets the un-
derlying chronic inflammation in COPD. As the first
approved selective PDE4 inhibitor, roflumilast reduces the
rate of exacerbations in patients with a high risk of future
exacerbations (GOLD patient groups C and D) and symp-
toms of chronic cough and sputum (chronic bronchitis)
[2,19,20]. A placebo-controlled clinical study has shownthat roflumilast reduces absolute neutrophil and eosinophil
counts in induced sputum [21]. However, evidence for its
anti-inflammatory effects is limited and warrants further
investigation in another study, in patients with COPD.
Accordingly, an ongoing clinical study has been de-
signed with the aim of increasing our understanding of
the anti-inflammatory effects of roflumilast. The study
will analyze inflammatory markers in bronchial biopsies,
induced sputum and blood serum and will offer the op-
portunity to identify potentially important biomarkers
and surrogate endpoints in patients with COPD. The
present paper brings the protocol of this clinical study to
the attention of the medical community and discusses
the rationale behind the study design.
Methods
Study design
An international, 16-week, randomized, double-blind,
placebo-controlled, parallel group study (Figure 1) inves-
tigating the effect of roflumilast 500 μg once daily versus
placebo on inflammation parameters in bronchial biopsy
tissue specimens, sputum and blood serum (clinical trial
identifier: NCT01509677). Patients will be equally random-
ized to either roflumilast treatment or placebo in a 1:1 ratio
by means of a computerized central randomization system
IVRS/IWRS. The system will assign one or two appropriate
trial treatment kit(s) from the stock available at the site
for each patient. The primary endpoint of the study will be
the number of CD8+ cells (cell counts per mm2) in bron-
chial biopsy tissue specimens (sub-mucosa) evaluated from
randomization to the end of the intervention period.
The key secondary endpoint will be the number of
CD68+ cells (cell counts per mm2), assessed over the
same timeframe, but a host of other secondary outcomes
will also be assessed (Table 1). The study will be con-
ducted at 11 European sites specializing in lung diseases.
Ethical considerations
This trial will be conducted in accordance with the Declar-
ation of Helsinki, Good Clinical Practice (GCP) guidelines
and any additional local regulations. Ethical approval has
been gained from the NRES Committee East of England -
Cambridge South, UK; Regionala etikprövningsnämnden i
Lund, Sweden; Komisja Bioetyczna UJ, Poland; Ethik-
Kommission der Ärztekammer Schleswig-Holstein (Ethik-
Kommission I), Germany as well as the UK, Swedish,
Polish and German regulatory agencies.
Patient population
Patients with a history of COPD for at least 12 months,
associated with chronic productive cough for at least three
months, in each of the two years prior to baseline visit will
be recruited into the study. Patients with moderate-to-
severe COPD (stages II and III) will be enrolled (according
Figure 1 Schematic design of the clinical study.
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cerbation (within six months prior to baseline) will be
excluded as will patients who have had a respiratory tract
infection, which has not resolved at least four weeks be-
fore baseline. Standard bronchodilator therapy use will
be permitted throughout the study. However, conco-
mitant medications, including glucocorticoids (inhaled
corticosteroids [ICSs]), oral steroids), long-acting β2-
agonist (LABA)/ICS combinations, theophylline, lipoxy-
genase inhibitors, anti-platelet therapy and leukotriene
antagonists will not be permitted throughout the trial
and will be withdrawn at the start of the run-in period.
Bronchodilators starting at least 6 weeks prior to run-in
will be allowed, although these treatments must remain
stable throughout the study. Other drugs for the treat-
ment of concurrent disease will be permitted, but their
doses must also be kept constant throughout study
(including the run-in period). In addition to meetingTable 1 Secondary endpoints evaluated from baseline or rand
period





Total and differential cell counts in
induced sputum, absolute (cells/mL) and





Concentration of inflammatory biomarkers:
Inflammatory mediators* (Human
InflammationMAP® v 1.0; Myriad RBM)
FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
*Alpha-1 antitrypsin, alpha-2 macroglobulin, beta-2 microglobulin, brain-derived ne
fibrinogen, granulocyte-macrophage colony-stimulating factor, haptoglobin, interce
IL-1 receptor antagonist, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40, IL-12 p70
inflammatory protein-1 beta, matrix metalloproteinase (MMP) type 2, MMP type 3, M
inhibitor of metalloproteinases 1, tumor necrosis factor (TNF)-alpha, TNF-beta, TNF-r
factor, von Willebrand factor, vitamin D-binding protein.the admission criteria (Table 2), patients must also sat-
isfy the following conditions in order to be eligible for
randomization into the double-blind treatment period:
 No COPD exacerbation between baseline and
randomization (as defined by treatment and/or
hospitalization)
 Tablet compliance ≥ 80% and ≤ 125%
Information regarding patients’ COPD severity (stage II
versus stage III), smoking status, concomitant LABA use
and previous inhaled corticosteroid usage will be recorded
for the purpose of sub-group analyses and stratification of
the most important confounding variables. The number of
enrolled patients will be capped at 150 in total.
Roflumilast and placebo tablets will be of identical
appearance, shape and colour and will have identical
labelling and packaging.omization to the end of the double-blind intervention
Blood serum Pulmonary function changes
Concentration of inflammatory
biomarkers: Inflammatory mediators*
(Human InflammationMAP® v 1.0;
Myriad RBM)
Change from randomization
to the end of the intervention
period:, FEV1FVC FEV1/FVC ratio
urotrophic factor, complement 3, C-reactive protein, eotaxin-1, factor VII, ferritin,
llular adhesion molecule-1, interferon gamma, interleukin (IL)-1 alpha, IL-1 beta,
, IL-15, IL-17, IL-23, macrophage inflammatory protein-1 alpha, macrophage
MP type 9, monocyte chemotactic protein-1, RANTES, stem cell factor, tissue
eceptor 2, vascular cell adhesion molecule-1, vascular endothelial growth
Table 2 Main inclusion and exclusion criteria
Main inclusion criteria Main exclusion criteria
Written informed consent obtained according to local regulations Clinical instability (exacerbation 6 months prior to
baseline as indicated by treatment)
History of COPD for at least 12 months prior to baseline, with chronic productive
cough for at least three months in each of the two years prior to baseline
Upper/lower respiratory tract infection not resolved 4
weeks prior to baseline
Outpatients 40–80 years of age Diagnosis of asthma and/or other relevant lung disease
or previous episodes of pneumothorax
Post-bronchodilator 30% ≤ FEV1 ≤ 80% predicted Known alpha-1 antitrypsin deficiency
Post-bronchodilator FEV1/FVC ratio ≤ 70% History of intubation for COPD or a respiratory failure of
any cause in the past year
Current or former smokers with smoking history ≥ 20 pack years Formal contraindications to sputum collection
Suspicion or diagnosis of a bleeding disorder irrespective
of its pathophysiological mechanism
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The sample size of 150 has been calculated from the
available information on the primary endpoint and has
been kept as small as possible. Previous trials have shown
that drop-out rates in bronchial biopsy studies may be as
high as 30% from enrolled patients; [16,17,22,23] there-
fore, if a conservative estimate of 30% is applied, the
present study may have 105 patients who complete the
trial. Drop-outs are difficult to handle in bronchial biopsy
studies. If drop-outs are excluded this could unfairly bias
the trial, however, if drop-outs continue in the study after
having treatment with antibiotics and systemic corticoste-
roids, this could also bias the results. It is therefore import-
ant to choose a group of patients who are unlikely to
exacerbate or drop out during the course of the trial, which
is the case in our study design. A universally recognized
level of clinical relevance regarding the primary endpoint
(sub-mucosal CD8+ cells) has not yet been agreed on
within the scientific community, but a 30% improvement
using roflumilast treatment over placebo may be of clin-
ical relevance. We have calculated that with a dispersion
of 25, tissue area of 0.3 mm2 and further assumptions
(1:1 randomization, two-sided α = 0.05, power = 0.90,
event rate on roflumilast = 200 cells/mm2, event rate on
placebo = 285 cells/mm2), the trial would have a high
power (approximately 90%) to detect treatment differ-
ences. However, the study will not be statistically pow-
ered to investigate any outcomes with regards to the
effectiveness of COPD treatment.
Technical aspects
Bronchoscopy
Bronchoscopies will be performed in line with the
American Thoracic Society (ATS) guidelines, [24] Endo-
bronchial Biopsy Workshop, [25] modified protocol of
O’Shaughnessy et al. [4] and according to local clinical
standards of care. Endobronchial biopsies will be taken
from each lobar and sub-segmental carina using Olym-
pus EndoJaw single-patient use biopsy cut forceps. Inorder to take into account both inter and intra-patient
variability, 2–3 biopsies will be taken from the lobar
bronchus and 2–3 from the sub-segmental airways, at
each bronchoscopy session (randomization and end of
treatment period). The left and right lobes will be alter-
nated between subjects, but all biopsies will be harvested
from the same lung during any given session. The sec-
ond set of biopsies (after the treatment period) will be
taken from the same airway level, but from a different
specific site.
In selected patients, three protected brush specimens
will be collected during the bronchoscopy procedures. If
performed, these specimens will be collected prior to the
bronchial biopsy procedure at the same part of the lower
lobe bronchus. The specimens will be used to evaluate
longitudinal changes in COPD airway microbiota in
placebo-treated patients and to define the effect of roflu-
milast therapy on the airway microbiome.
Biopsy sample processing, cell quantification and biopsy
quality
Biopsies will be gently extracted and sent to the site’s
laboratory for further processing (fixation and paraffin
wax embedding). Immunostaining and quantification of
inflammatory cells will be performed according to stand-
ard procedures [4,23,25,26]. Briefly, inflammatory cells
will be identified using indirect immunohistochemistry
(using the peroxidase-antiperoxidase complex-PAP- and di-
aminobenzidine as substrate or the alkaline phosphatase-
anti-alkaline phosphatase complex; APAAP and Fast Red).
For each antibody, the total number of positively stained
cells will be counted to a depth of 100 μm below the epi-
thelial basement membrane using a computerized image
analysis.
To ensure adequate quality and consistency between
investigators at different sites, centralized training, cov-
ering all aspects of material collection, handling and
processing, will be provided. The quality of biopsy ma-
terial will also be validated for each site, by requesting
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three enrolled patients. In order to be considered a good
quality sample, the biopsied tissue area must be ≥0.1 mm2,
contain ≥1 mm of basement membrane and be ≥100 μm
deep. Only after the biopsy samples are considered to be
of sufficiently good quality will the site be allowed to re-
cruit further patients into the trial.Inflammatory biomarkers in induced sputum
Sputum will be induced, collected and initially processed
at investigational sites. The quality of sputum samples will
also be estimated by investigators on a scale from one to
six. Total and differential cell counts of neutrophils, mac-
rophages, eosinophils and lymphocytes will be performed
and inflammatory biomarkers will be analyzed using the
46-biomarker Multi-Analyte Profiling (MAP) technology
(Human InflammationMAP® v 1.0; Myriad RBM). This
tool contains quantitative, multiplexed immunoassays
for 46 biomarkers, but the ones of primary interest
with regards to this study and roflumilast will be:
alpha-2 macroglobulin, interleukin-8 (IL-8), monocyte
chemotactic protein-1 (MCP-1), matrix metallopro-
teinase type 9 (MMP-9), tissue inhibitor of metallopro-
teinase (TIMP) and vascular endothelial growth factor
(VEGF). The remaining 40 biomarkers will only be
analyzed exploratively (Table 1). To ensure adequate qual-
ity and consistency of samples, centralized hands-on train-
ing will be provided and samples will be assessed on an
ongoing basis.Inflammatory biomarkers in blood serum
Blood withdrawal for the measurement of inflammatory
biomarkers will be performed at approximately the same
time each day (±2 hours), but no later than 10:00 am at
each respective visit. Inflammatory biomarkers will be
quantified using MAP technology (Human Inflamma-
tionMAP® v 1.0; Myriad RBM).
Blood serum, sputum and biopsy samples will be col-
lected and appropriately stored for up to three years
after the end of the study to allow for future analyses of
biomarkers of scientific interest.Pulmonary function tests
Spirometry will be performed according to the recom-
mendation of the ATS – European Respiratory Society
(ATS/ERS) consensus guidelines on pulmonary function
testing [27]. Sites will use their own devices, performing
maintenance and calibration of instruments according
to usual standards of practice. FEV1 (absolute and per-
centage predicted values), forced vital capacity (FVC)
(absolute values) and the ratio of FEV1/FVC will also be
recorded.Safety
Following bronchoscopy with bronchial biopsy, patients
will be closely monitored for at least two hours and will
only be discharged when the effects of sedation and local
anaesthesia disappear as judged by the investigator. All pa-
tients will be provided with a 24-hour emergency contact
number and a safety follow-up visit will be performed
within two weeks after each bronchoscopy session.
Statistical and analytical plans
The intention-to-treat (ITT) analysis will be based on
the full analysis set (FAS). It will be the primary analysis
for this study and will be performed for all primary and
secondary endpoints. The primary endpoint relates to
pulmonary inflammation expressed as CD8+ cell counts
per mm2 in sub-mucosal bronchial biopsy tissue speci-
mens measured before and after the double-blind treat-
ment period. The key secondary endpoint relates to
CD68+ cell counts per mm2 in sub-mucosal bronchial
biopsy tissue specimens. Roflumilast/placebo compari-
sons for these endpoints will be performed via a multiple
test procedure such that the family-wise error rate of 5%
is controlled in the strong sense. The two null hypoth-
eses are: equal CD8+ counts/mm2 and equal CD68+
counts/mm2 for roflumilast and placebo. These null hy-
potheses will be ordered, so that the CD8+ comparison
comes first and the CD68+ comparison comes second. If
the comparison with respect to CD8+ is significant at
the nominal level α = 5%, the corresponding null hypoth-
esis will be rejected and the CD68+ comparison will be
performed in a confirmatory way (otherwise confirma-
tory testing stops). This will again be done at nominal
level α = 5%. If significant (after a significant result in the
first comparison), the corresponding null hypothesis will
be rejected. If the first comparison is not significant at 5%
level, then neither null hypothesis must be rejected. The
component tests of the multiple test on CD8+ and CD68+
will be based on Poisson regression models with CD8+
(CD68+) at end of treatment period as a dependent vari-
able and treatment and baseline values of the respective
dependent variable as covariates. A dispersion parameter
and an offset (equivalent to the bronchoscopy sampling
area) will be taken into account.
Analyses of the other secondary endpoints will be de-
scriptive on treatment and visit, by ANCOVA on absolute
change from baseline to last available measurement during
double-blind treatment for continuous variables, or Pois-
son regression for count data. In addition, analyses will be
performed in subgroups stratified by COPD stage, smok-
ing status, concomitant LABA and former ICS use.
Discussion
This clinical study hypothesizes that roflumilast reduces
the characteristic inflammation of COPD in patients
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flammation has been characterized in the airways and
lung parenchyma of COPD patients, predominantly con-
sisting of increased numbers of CD8+ T-lymphocytes,
CD68+ cells and neutrophils [3-8]. Previous research has
shown that inflammatory mediators, such as IL-6 and
IL-8, also play an important role in COPD [10]. Roflumi-
last reduces exacerbations in patients with moderate-to-
severe COPD and chronic bronchitis, [19] but there are
limited clinical data on its anti-inflammatory effects in
the lungs as well as systemically [21]. The present study
was designed to implement lessons learned from previ-
ous bronchial biopsy studies. It will hope to reveal the
precise anti-inflammatory properties of roflumilast re-
sponsible for its therapeutic effect in the lungs (biopsy
and sputum) and identify potentially important bio-
markers and surrogate endpoints in patients with
COPD. Moreover, the results from this study may also
provide a better understanding of the pathophysiology
of COPD and serve as a foundation for future research.
Rationale behind the study design
This will be the first study to associate roflumilast’s ef-
fects in sputum, the lungs and systemic circulation with
observed anti-inflammatory changes. Previous studies
have pinpointed CD8+ T-lymphocytes and macrophages
(CD68+) as cell populations characteristic in COPD in-
flammation [3-8]. Based on these data, CD8+ and CD68+
cell counts have been selected as the respective key
primary and secondary endpoints for this study. The
measurement of cell counts per mm2 was selected on
the basis that the area profile count is a commonly used
method for the quantification of inflammatory cells in
bronchial biopsies [16,17,23,28]. Induced sputum offers
another opportunity to obtain samples containing po-
tentially valuable information on disease characteristics,
relatively easily; while the collection of blood serum for
biomarker analyses is based on the hypothesis that sys-
temic inflammation and oxidative stress contribute to
the pathogenesis of COPD. It may be argued that the
endpoints used in this study are neglecting the most im-
portant site of inflammation in COPD – the small air-
ways. However, until safe and reliable methods, which
can detect small airway inflammation accurately are de-
veloped, the analysis of bronchial biopsies will remain a
valuable technique for sampling COPD inflammation.
Roflumilast is effective after only four weeks of treat-
ment, [21] and longer studies have shown similarly con-
sistent clinical improvements [19]. Based on these data
and other studies that have revealed anti-inflammatory
treatment effects over 3 months, [16,17] a treatment
period of 16 weeks has been selected as an optimal length
of time to collect information on the anti-inflammatory
effects of roflumilast, while allowing sufficient time forpatients to fully recover between interventions. A 6-week
single-blind run-in period has been incorporated into the
study schedule to assess patients’ compliance and for rea-
sons of standardization.
Steps have been taken to reduce factors that contribute
to intra- and inter-patient variation when obtaining sam-
ples. Work by Gamble et al. has shown that endobronchial
biopsies from more than one airway generation should be
examined in order to maximize statistical power [29]; in
this study, 2–3 endobronchial biopsies will be taken from
each lobar and sub-segmental carina. At the same time,
consistency between investigators and sites will be ensured
by way of centralized training. Sites will also be requested
to provide biopsy and sputum samples for quality evalu-
ation before they are allowed to enrol further patients.
Selecting the most appropriate patient population for
bronchial biopsy studies is an important factor. Ethically,
it is not appropriate to subject patients in the indicated
roflumilast patient population to the procedures re-
quired in this study, since it may put them at increased
risk. Furthermore, if patients experience exacerbations
during the study and require treatment with steroids or
antibiotics, it would confound the analysis of the study
and make it difficult to ascertain the effects of roflumi-
last on inflammation. With this in mind, patients with
moderate-to-severe COPD (stages II and III) according
to GOLD 2009 were chosen for this study. These pa-
tients were considered to be stable enough to be subject
to bronchoscopy with bronchial biopsy and sputum col-
lection. Although they are not exactly the indicated
roflumilast population, it is important to note that roflu-
milast improves lung function in patients with stable
disease too, regardless of exacerbation history [30,31].
Therefore, the study design provides us with a valuable
opportunity to obtain information on the effects of roflu-
milast in patients with more stable disease, who have not
previously been investigated [3]. All patients will continue
to receive standard bronchodilator therapy throughout the
trial, thereby ethically justifying the placebo arm of the
study. Moreover, allowing the use of bronchodilator ther-
apy throughout the trial will also show the effects of roflu-
milast on top of standard therapy.
The safety of enrolled patients is another important
consideration, especially in an invasive study of this kind.
Hattotuwa et al. have shown that fibre optic bronchos-
copy with bronchial biopsy are procedures that can be
performed in research patients with COPD (even with
severe disease), with a low incidence of adverse events
[32]. Nevertheless, there are risks associated with bron-
choscopy such as bleeding, discomfort and coughing,
although serious adverse events such as lung leak and
pneumothorax are rare [33]. A number of approaches
will help to minimize these safety pitfalls in this study.
Firstly, bronchoscopies with bronchial biopsies will only
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have demonstrated that they are able to perform these
techniques in a standardized and safe manner, in previ-
ous clinical studies. Secondly, standardized procedures
will be followed by each site. Thirdly, dedicated safety
follow-up visits have been included in the study schedule
and fourthly, sputum collection will alternate with
bronchoscopy visits to limit the number of interven-
tions performed on any given day. Finally, although
class-specific adverse events have been reported in pre-
vious clinical studies with roflumilast, the treatment has
at the same time proved to be effective in COPD pa-
tients with moderate-to-very severe airflow limitation
[19,34]. Nevertheless, drug-specific adverse events will
be closely monitored and recorded throughout the
study.Conclusions
This bronchial biopsy trial will increase our understanding
of the anti-inflammatory effects of roflumilast in COPD.
Roflumilast reduces COPD exacerbations, but its actions
in the lungs, particularly its anti-inflammatory activities,
are not well understood. A better comprehension of the
effects of roflumilast on inflammatory cells and mediators
may help in identifying patients who would benefit most
from treatment. It would also improve our understanding
of which measurable parameters (e.g. cell counts, activities
and mediators) might serve as surrogate predictors for the
clinical efficacy of roflumilast.Abbreviations
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